Investigation on the effects of topical therapy with 0.1% tacrolimus ointment (Protopic®) on intradermal skin test reactivity in atopic dogs

Veterinary Dermatology

Volumn 15, Issue 4, 2004, Pages 218-224

  Marsella, R ^a   Nicklin, C F ^a   Saglio, S ^a   Lopez, J ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

Atopic dermatitis; Dogs; Intradermal skin test; Tacrolimus

Indexed keywords

HISTAMINE; LIPOPOLYSACCHARIDE; SODIUM CHLORIDE; TSUKUBAENOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; COMPUTER PROGRAM; CONTROLLED STUDY; DATA ANALYSIS; DOG; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MODEL; HOUSE DUST; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MITE; NONHUMAN; REACTION ANALYSIS; SKIN MANIFESTATION; SKIN TEST; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, CUTANEOUS; ALLERGENS; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; CROSS-OVER STUDIES; DERMATITIS, ATOPIC; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FALSE NEGATIVE REACTIONS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTRADERMAL TESTS; MALE; OINTMENTS; SKIN; TACROLIMUS;

ACARI; ANIMALIA; ASTIGMATA; CANIS FAMILIARIS; PYROGLYPHIDAE;

EID: 4444230518     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2004.00387.x     Document Type: Article

References (45)

1. Lazarus MC, Kerdel FA. Topical tacrolimus Protopic. Drugs of Today (Barcelona) 2002; 38: 7-15.
2. Rustin M. Tacrolimus ointment for the management of atopic dermatitis. Hospital Medicine 2003; 64: 214-17.
3. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK-506. Immunology Today 1992; 13: 136-42.
4. Kino T, Hatanaka H, Hashimoto M et al. FK-506, a novel immunosuppressant isolated from Streptomyces I. Fermentation, isolation, physico-chemical and biological characteristics. Journal of Antibiotics 1987; 40: 1249-55.
5. de Paulis A, Stellato C, Cirillo R et al. Anti-inflammatory effect of FK-506 on human skin mast cells. Journal of Investigative Dermatology 1992; 99: 723-8.
6. Thomson AW, Nalesnik M, Abu-Elmagd K et al. The influence of FK-506 on T lymphocytes, Langerhans' cells, and the expression of cytokine receptors and adhesion molecules in psoriatic skin: a preliminary study. Transplantation Proceedings 1991; 23: 3330-1.
7. Aoyama H, Tabata N, Tanaka M et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK-506 ointment. British Journal of Dermatology 1995; 133: 494-6.
8. Paller A, Eichenfield LF, Leung DYM et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. Journal of the American Academy of Dermatology 2001; 44: S47-57.
9. Koshika T, Ishizaka A, Nagatomi I et al. Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury. American Journal of Respiratory and Critical Care Medicine 2001; 163: 79-84.
10. Marsella R, Nicklin CF. Double blinded-placebo controlled, cross-over study to evaluate the efficacy and safety of 0.3% topical tacrolimus in canine atopic dermatitis. Veterinary Dermatology 2002; 13: 203-10.
11. Marsella R, Nicklin CF, Saglio S et al. Investigation on the efficacy and safety of 0.1% tacrolimus ointment (Protopic®) in canine atopic dermatitis: a randomized, double blinded, placebo controlled cross over study. In: Proceedings of the 18th Annual Meeting of the American College and the American Academy of Veterinary Dermatology. Monterey, CA, 2003: 221.
12. Marsella R, Nicklin CF. Sulphido-leukotriene production from peripheral leukocytes and skin in clinically normal dogs and house dust mite positive atopic dogs. Veterinary Dermatology 2001; 12: 3-12.
13. Satoh T, Tahara E, Yamada et al. Differential effect of anti-allergic drugs on IgE-mediated cutaneous reaction in passively sensitized mice. Pharmacology 2000; 60: 97-104.
14. Queille-Roussel C, Graeber M, Thurston M et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42: 349-50.
15. Geba GP, Ptak W, Askenase PW. Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity. Immunology 2001; 104: 235-42.
16. Sengoku T, Morita K, Sakuma S et al. Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models. European Journal of Pharmacology 1999; 379: 183-9.
17. Sengoku T, Morita K, Sato S et al. Effects of tacrolimus ointment on type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice (in Japanese). Nippon Yakurigaku Zasshi Folia Pharmacologica Japonica 1998; 112: 221-32.
18. Gaga M, Frew AJ, Varney VA et al. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. Journal of Immunology 1991; 147: 816-22.
19. Barata LT, Ying S, Meng Q et al. IL-4- and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects. Journal of Allergy and Clinical Immunology 1998; 101: 222-30.
20. Okada M, Terui T, Honda M et al. Cutaneous late phase reaction in adult atopic dermatitis patients with high serum IgE antibody to Dermatophagoides farinae: correlation with IL-5 production by allergen-stimulated peripheral blood mononuclear cells. Journal of Dermatological Science 2002; 29: 73-84.
21. Zweiman B, Parrott CM, Graif Y et al. Quantitative comparison of cytokine mRNA and inflammatory responses in cutaneous late phase allergic reactions. Cytokine 2000; 12: 1065-75.
22. Ying S, Robinson DS, Meng Q et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). Journal of Immunology 1999; 163: 3976-84.
23. Zweiman B, Von Allmen C. Temporal patterns of mediator release during developing cutaneous late-phase reactions. Clinical and Experimental Allergy 2000; 30: 856-62.
24. Olivry T, Dunston SM, Murphy KM et al. Characterization of the inflammatory infiltrate during IgE-mediated late phase reactions in the skin of normal and atopic dogs. Veterinary Dermatology 2001; 12: 49-58.
25. Olivry T, Naydan DK, Moore PF. Characterization of the cutaneous inflammatory infiltrate in canine atopic dermatitis. American Journal of Dermatopathology 1997; 19: 477-86.
26. Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. Journal of Pharmacology and Experimental Therapeutics 1992; 260: 680-8.
27. Wershil BK, Furuta GT, Lavigne JA et al. Dexamethasone or cyclosporin A suppresses mast cell-leukocyte cytokine cascades. Multiple mechanisms of inhibition of IgE- and mast cell-dependent cutaneous inflammation in the mouse. Journal of Immunology 1995; 154: 1391-8.
28. Kohyama T, Takizawa H, Kawasaki S et al. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. Molecular Cell Biology Research Communications 1999; 1: 72-7.
29. Conti P, Pang X, Boucher W et al. RANTES is a proinflammatory chemokine and chemoattracts basophil cells to extravascular sites. Journal of Pathology 1997; 183: 352-8.
30. Silber A, Newman W, Reimann KA et al. Kinetic expression of endothelial adhesion molecules and relationship to leukocyte recruitment in two cutaneous models of inflammation. Laboratory Investigation: a Journal of Technical Methods and Pathology 1994; 70: 163-75.
31. Inagawa H, Nishizawa T, Takagi K et al. Antitumor mechanism of intradermal administration of lipopolysaccharide. Anticancer Research 1997; 17: 1961-4.
32. Issekutz AC, Issekutz TB. Quantitation and kinetics of blood monocyte migration to acute inflammatory reactions, and IL-1 alpha, tumor necrosis factor-alpha, and IFN-gamma. Journal of Immunology 1993; 151: 2105-15.
33. Andersson J, Nagy S, Groth CG et al. The effects of FK 506 on cytokine production are dependent on the mode of cell activation. Transplantation Proceedings 1991; 23: 2916-19.
34. Walliser P, Benzie CR, Kay JE. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. Immunology 1989; 68: 434-5.
35. Yoshimura N, Matsui S, Hamashima T et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation 1989; 47: 356-9.
36. Sakuma S, Kato Y, Nishigaki F et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. British Journal of Pharmacology 2000; 130: 1655-63.
37. Tocci MJ, Matkovich DA, Collier KA et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. Journal of Immunology 1989; 143: 718-26.
38. Nagai H, Hiyama H, Matsuo A et al. FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. Journal of Pharmacology and Experimental Therapeutics 1997; 283: 321-7.
39. Kawamura N, Furuta H, Tame A et al. Extremely high serum level of IgE during immunosuppressive therapy: paradoxical effect of cyclosporine A and tacrolimus. International Archives of Allergy and Immunology 1997; 112: 422-4.
40. Wheeler DJ, Robins A, Pritchard DI et al. Potentiation of vitro synthesis of human IgE by cyclosporin A (CsA). Clinical and Experimental Immunology 1995; 102: 85-90.
41. Clarke K, Mccall C, Steffan J. The effects of cyclosporine A and oral prednisolone on flea allergen specific serum IgE and intradermal tests in experimentally sensitized laboratory beagles. In: Proceedings of the 18th European Society and European College of Veterinary Dermatology. Nice, France, 2002: 223.
42. van den Berg AP, van Son WJ, Haagsma EB et al. Prediction of the inhibition of IL-2 production by calcineurin inhibitors. Transplantation Proceedings 2001; 33: 1076-7.
43. Burton G, Robson D, Bassett R et al. A pilot trial on the effect of cyclosporine on intradermal skin testing in dogs with atopic dermatitis. In: Proceedings of the 17th annual meeting of the American College and the American Academy of Veterinary Dermatology. New Orleans, LA, 2002: 20.
44. Remitz A, Lauerma AI, Erkko P et al. Delayed-type hypersensitivity in palmoplantar pustulosis: effect of cyclosporin A treatment on skin testing with recall antigens. Acta Dermato-Venereologica 1996; 76: 310-13.
45. Munro CS, Higgins EM, Marks JM et al. Cyclosporin A in atopic dermatitis: therapeutic effect and effect on allergic reactions are dissociated from each other. Wiener Medizinische Wochenschrift 1991; 141: 419-23.